Podium Presentation Stem Cells

23.4.1 - Allogeneic and autologous equine mesenchymal stem cells elicit comparable responses in both normal and inflamed equine joints

Presentation Number
23.4.1
Presentation Topic
Stem Cells
Lecture Time
10:30 - 10:39
Session Type
Free Papers
Corresponding Author
  • A. Colbath (Fort Collins, US)
Authors
  • A. Colbath (Fort Collins, US)
  • S. Dow (Fort Collins, US)
  • J. Phillips (Fort Collins, US)
  • L. Goodrich (Fort Collins, US)
Disclosure
L. Goodrich, Advanced Regenerative Therapies, Shareholder.

Abstract

Purpose

Allogeneic equine bone marrow-derived mesenchymal stem cells (BMDMSCs) offer multiple clinical advantages over autologous BMDMSCs. Prior to clinical use, the safety and effectiveness of allogeneic versus autologous BMDMSCs must be determined. The purpose of the study was to evaluate the normal equine joint and inflamed equine joint reaction to allogeneic and autologous BMDMSCs.

Methods and Materials

Eight horses were used in the study. Autologous and pooled-allogeneic BMDMSCs were culture expanded, cryopreserved and thawed prior to administration. Clinical parameters (lameness, joint circumference and joint effusion) and synovial fluid parameters including nucleated cell count, differential cell count, total protein, prostaglandin E2 (PGE2) and C-reactive protein (CRP) were measured prior to intra-articular administration and 6, 12, 24, 72, 168, and 336 hours post-injection. Ten million autologous and allogeneic BMDMSCs were administered into contralateral (non-inflamed) metacarpophalangeal joints. After a 3 week washout period, 75ng of recombinent equine interleukin-1β (rIL-1β) and 10 million autologous BMDMSCs were administered into one tibiotarsal joint. After an additional one week period, the contralateral tibiotarsal joint received allogeneic BMDMSC plus 75ng rIL-1β. Four additional horses received 75ng rIL-1β alone in a single tibiotarsal joint.

Results

No difference was detected in any clinical or cytological parameters between (non-inflamed) metacarpophalangeal joints administered autologous or allogeneic BMDMSCs. In addition, no difference was detected in subjective lameness, joint effusion, joint circumference, NCC, TP, differential cell count, CRP or PGE2 of inflamed joints administered autologous versus allogeneic BMDMSCs. Neither autologous nor allogeneic BMDMSCs resulted in any improvement in clinical or cytological parameters when compared to rIL-1β alone.

Conclusion

The study found no clinical or cytological differences in the normal joint response to autologous or allogeneic BMDMSCs. In addition, the study revealed no difference in the inflamed equine joint response to autologous or allogeneic BMDMSCs. Further, autologous and allogeneic BMDMSCs were equally ineffective in reducing the inflammatory response resulting from rIL-1β administration.

Collapse